[Federal Register Volume 85, Number 38 (Wednesday, February 26, 2020)]
[Notices]
[Pages 11053-11054]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03788]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee Meeting
AGENCY: Under Secretary of Defense for Personnel and Readiness,
Department of Defense (DoD).
ACTION: Notice of Federal Advisory Committee meeting.
-----------------------------------------------------------------------
SUMMARY: The DoD is publishing this notice to announce that the
following Federal Advisory Committee meeting of the Uniform Formulary
Beneficiary Advisory Panel (UFBAP) will take place.
DATES: Open to the public Wednesday, April 1, 2020, from 9:00 a.m. to
12:00 p.m.
ADDRESSES: The address of the open meeting is the Naval Heritage Center
Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004.
FOR FURTHER INFORMATION CONTACT: Colonel Paul J. Hoerner, U.S. Air
Force, 703-681-2890 (Voice), None (Facsimile), [email protected] (Email). Mailing address is 7700 Arlington
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: https://health.mil/bap. The most up-to-date changes to the meeting agenda can
be found on the website.
SUPPLEMENTARY INFORMATION: This meeting is being held under the
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5
U.S.C., Appendix, as amended), the Government in the Sunshine Act of
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
The UFBAP will review and comment on recommendations made to the
Director of the Defense Health Agency, by the Pharmacy and Therapeutics
Committee, regarding the Uniform Formulary.
Purpose of the Meeting: The DoD is publishing this notice to
announce that the following Federal Advisory Committee meeting of the
UFBAP will take place.
Agenda: Wednesday, April 1, 2020, from 9:00 am to 12:00 pm
1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews (Comments will follow each
agenda item)
a. Pain Agents--Non-Steroidal Anti-Inflammatory Drug (NSAID)
b. Pain Agents--Topical Pain
4. Newly Approved Drugs Review
5. Pertinent Utilization Management Issues
6. UFBAP Discussions and Vote
Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and
41 CFR 102-3.140 through 102-3.165, this meeting is open to the public,
subject to the availability of space. Seating is limited and will be
provided to the first 220 people. All persons must sign in legibly.
Written Statements: Pursuant to 41 CFR 102-3.140, and section
10(a)(3) of FACA, interested persons or organizations may submit
written statements to the UFBAP about its mission and/or the agenda to
be addressed in this public meeting. Written statements should be
submitted to the UFBAP's Designated Federal Officer (DFO). The DFO's
contact information can be found in the FOR FURTHER INFORMATION CONTACT
section of this notice. Written comments or statements must be received
by the UFBAP's DFO at least five (5) business days prior to the meeting
so they may
[[Page 11054]]
be made available to the UFBAP for its consideration prior to the
meeting. The DFO will review all submitted written statements and
provide copies to all UFBAP members.
Dated: February 20, 2020.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2020-03788 Filed 2-25-20; 8:45 am]
BILLING CODE 5001-06-P